CYTOKINETICS INCORPORATED - COMMON STOCK

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

03 Jan 2025 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

23 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

20 Dec 2024 00:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Dec 2024 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction

03 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics to Participate in December Investor Conferences

02 Dec 2024 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

02 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan

19 Nov 2024 02:30:00 By Nasdaq GlobeNewswire

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024

16 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024

16 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference

12 Nov 2024 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089

11 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics Reports Third Quarter 2024 Financial Results

06 Nov 2024 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024

05 Nov 2024 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Nov 2024 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Announce Third Quarter Results on November 6, 2024

23 Oct 2024 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day

16 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Oct 2024 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Host Investor & Analyst Day on October 16, 2024

02 Oct 2024 16:00:00 By Nasdaq GlobeNewswire